CRLF2 is a member of type I cytokine receptor family. CRLF2 forms a functional complex with IL-7 receptor α chain and thymic stromal lymphopoietin, this complex induces the activation of signal transducers and activators of transcription proteins. The overexpression of CRLF2 induced by genetic rearrangements has been described in acute lymphoblastic leukemia.
. Chromosomes obtained from MHH-CALL-4 cell line positive to IGH/CRLF2 translocation detected by fluorescence in situ hybridization (FISH) . The der(Y) chromosome is lost in the cell line. Metaphase hybridized with CRLF2 break-apart probe (Cytocell Aquarius) with a normal chromosome X (green-red signal, yellow arrow), and der(14) (green signal, white arrow). 
DNA/RNA
Description CRLF2 gene is located in reverse strand of pseudoautosomal region 1 (PAR1) in X and Y chromosomes. CRLF2 encompasses 22kb of DNA and give rise to four transcript variants with different lengths: 1.6, 1.5, 1.0 and 1.7 kb. ENSG00000205755 Transcription CRLF2 gene encodes a member of type I cytokine receptor family and generate four transcript variants ( 
Protein
Description CRLF2 gene encodes a member of the type I cytokine receptor family. CRLF2 has three protein coding transcripts: CRLF2-201, CRLF2-202, CRLF2-203 and CRLF2-204. CRLF2-203 and CRLF2-201 transcript variants generate the longer isoform of 371 amino acids (42 kDa), also called isoform 1. Isoform 1 has the protein regions that characterize this family gene: FN3 (Fibronectin type 3) region, WSXWS motif, Box 1 motif, and transmembrane region. Post-translational modifications of CRLF2 protein include glycosylation at asparagine residues (Asn169, Asn55 and Asn47) and phosphorylation at isoleucine (Ile271) and tyrosine (Tyr74) residues. The other isoform, called isoform 2, is encoded by the transcript variant CRLF2-202. This isoform is shorter, 259 amino acids (26.6 kDa), at N-terminus compared with isoform 1 because lacks an alternate exon which results in translation initiation at a downstream start codon. ENSG00000205755; UniProt Q9HC73, Q9HC73-2, Q4V300; neXtProt NX_Q9HC73 Expression CRLF2 protein is present in intestine, bone marrow, spleen, thymus, and is more abundant in dendritic cells. neXtProt NX_Q9HC73 Localisation CRLF2 isoform 1 is a cell membrane protein and CRLF2 isoform 2 is a secreted protein.
Function
CRLF2 forms a functional complex with IL-7Rα (IL-7 receptor α chain) and TSLP (thymic stromal lymphopoietin). Functional complex activation induces different signals depending on the type of cell and also exerts multiple functions. Heterocomplex is involved in a plethora of physiologic and pathologic immune functions, including: tolerance, allergy, autoimmune diseases and cancer. (Tsilingin et al., 2017) . CRLF2 is expressed mainly in dendritic cells and also hematopoietic cells including T cells, B cells, granulocytes, and mast cells. Heterocomplex main function is the differentiation to T helper type 2 (Th2) cells. CRLF2-activated dendritic cells express OX40 ligand and trigger naive CD4 + to differentiate into inflammatory Th2 cells and the expansion of allergen-specific Th2 memory cells (Lin et al., 2018) . According with phosphoproteome analysis in diverse cell types, after TSLP binds to the CRLF2/IL-7Rα heterocomplex, the phosphorylation of Janus kinase1 (JAK1) and 2 (JAK2) activates signal transducers and activators of transcription (STATs) proteins, including: STAT1, STAT3, STAT4, STAT5A, STAT5B and STAT6. Heterocomplex also activates other signaling molecules such as PI3K/AKT/MTOR pathway, SRC / TEC pathway, MAPK3 / MAPK1 (ERK1/2), NF-kB, MAPK8 / MAPK9 (JNK1 JNK2), and p38/MAPK activation (Zhong Jun et al., 2012; Zhong Jun et al., 2014) .
In allergy or autoimmune disease has been described high expression of TSLP and overstimulation of TSLP/CRLF2/IL-7Rα complex. Tezepelumab is a human monoclonal antibody that blocks functional complex and is successfully used in asthma treatment (Van Rompaey et al., 2012) .
CRLF2 (Cytokine receptor like factor 2)
Moreno-Lorenzana D et al.
Atlas Genet Cytogenet Oncol Haematol. 2020; 24(1) 4 Figure 5 . A) TSLP /CRLF2/ IL7R complex activation is implicated in Th2 differentiation. TSLP binds to CRLF2/IL-7Rα heterodimer in dendritic cells and promotes the expression of OX40 ligand ( TNFSF4 (CD252)) and IL13, IL5, IL4 and TNF to induce Th2 differentiation. B) TSLP/CRLF2/IL-7Rα complex activation in dendritic cells. Activation of CRLF2 was described by first time in dendritic cells. This scheme exemplifies the main nodes involved.
The role of functional heterocomplex in cancer is still controversial, in certain neoplasia plays a protumorigenic role, whereas in others, a protective role. For example, in cervix, breast, and pancreas cancer has been describe an increase of metastasis associated with an overstimulation of TSLP/CRLF2/IL-7Rα. On the other hand, in colon and skin carcinoma, functional heterocomplex has been associated with better prognostic. In addition to above, CRLF2 gene has genetic alterations that promote cell survival in cancer. The genetic rearrangements P2RY8/CRLF2 and IGH/CRLF2, generate CRLF2 overexpression, and the mutation Phe232Cys, encodes CRLF2 proteins capable of forming homodimers and self-activation, both described in acute lymphoblastic leukemia (Varricchi et al., 2018; Zhong Jun, 2014) . 
Homology
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Oncogenesis The t(X;14)(p22;q32) or t(Y;14)(p11;q32) rearrange CRLF2 with immunoglobulin heavy chain gene forming IGH/CRLF2 rearrangement. With P2Y purinoceptor 8 gene ( P2RY8), located also in the pseudoautosomal (PAR1) region of X or Y chromosomes, CRLF2 forms a rearrangement through the interstitial deletions del(X)(p22p22) or del(Y)(p11p11). Both abnormalities are associated with B-precursor acute lymphoblastic leukemia (pre-B ALL) and Down syndrome pre-B ALL (Entrez Gene ID: 64109; Russell LJ et al., 2009 ). It has been referred similar deletions in the PAR1 region involving the interleukin 3 receptor subunit alpha ( IL3RA) gene or the colony stimulating factor 2 receptor alpha subunit (CSF2RA) gene and CRLF2, indicating that the breakpoints are variable between patients. Interestingly, one patient has been reported with the CSF2RA/CRLF2 rearrangement and IGH/ EPOR (Yano M et al., 2015) . These rearrangements produce the overexpression of CRLF2 by the juxtaposition of this gene within the gene promoter of P2RY8, AKAP17A (SFRS17A), or ASMT (Russell LJ et al., 2009) . Biallelic deletions of the PAR1 region, including CSF2RA and CRLF2 genes, have been reported in mantle cell lymphoma (Nieländer I et al., 2008) . In addition, four fusions with CRLF2 have been also reported: 1) CHRFAM7A /CRLF2 with the cholinergic receptor, nicotinic, alpha 7, exons 5-10 and he family with sequence similarity 7A, exons A-E fusion gene (CHRNA7) located in 15q13 (Fusion gen ID: 7161); 2) CRLF2/ U2AF1 with the U2 small nuclear RNA auxiliary factor 1 gene (U2F1), associated with myelodysplastic syndrome, and located in 21q22.3 (Fusion gen ID: 8499); 3) GOLGA8A /CRLF2 with the golgin A8 family member A gene (GOLGA8A) in 15q14 (Fusion gen ID: 15056); 4) WDR27 /CRLF2 with the WD repeat domain 27 gene (WDR27) in 6q27 (Fusion gen ID: 41824).
Pulmonary alveolar proteinosis
A recessive pattern of another similar homozygous deletion, that disrupts CSF2RA, CRLF2, and IL3RA gene, was found in a boy with pulmonary alveolar proteinosis, an accumulation of surfactant in the alveoli. Surfactant is cleared by alveolar macrophages, and granulocyte-macrophage colonystimulating factor (GM-CSF) and its signaling is necessary for this process. GM-CSF activates Jak-Stat pathway inducing phagocytic functions of alveolar macrophage and catabolize surfactant (Chiu CY et al., 2017) .
